Aguilar-Salinas CA, Rojas R, Gómez-Pérez FJ, Valles V, Franco A, Olaiz G, Tapia-Conyer R, Sepúlveda J, Rull JA

Idioma: Español
Referencias bibliográficas: 31
Paginas: 546-553
Archivo PDF: 125.85 Kb.

RESUMEN

Objetivo. Describir las características de los pacientes con hiperlipidemia mixta de acuerdo con los datos derivados de la Encuesta Nacional de Enfermedades Crónicas. Material y métodos. Se realizó una entrevista en 1993, en 417 ciudades del país, y se midieron las concentraciones sanguíneas de lípidos séricos, glucosa e insulina en 2 206 casos en un estudio poblacional. La diferencia entre los pacientes con dislipidemias mixtas y el resto de la población se estableció utilizando análisis de varianza o la prueba de ji cuadrada. Resultados. La hiperlipidemia mixta se encontró en 282 casos (12.8%). Los individuos afectados tenían 42.7 ± 12.6 años. El 56% eran hombres; 46.4% tenían un colesterol HDL ‹ 0.9 mmol/l. La presencia de otros factores de riesgo fue común. La prevalencia de las hiperlipidemias mixtas fue alta aun en adultos jóvenes. Por medio de un modelo de regresión logística fue posible identificar la obesidad, la edad, el género, la región del país en donde residía el sujeto, la presencia de diabetes o de hipertensión arterial y la concentración de insulina de ayuno ›21 mU/ml como anormalidades asociadas a las dislipidemias mixtas. Conclusiones. La dislipidemia mixta es muy frecuente en adultos mexicanos. Se observa predominantemente en hombres mayores de 30 años y los casos tienen otros factores de riesgo cardiovascular. Los datos sugieren que el síndrome metabólico participa en la génesis de la dislipidemia mixta.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Austin M, Hokanson JE, Edwards K. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81(4A): 7B-12B.

2. Kesäniemi YA. Serum triglycerides and clinical benefit in lipid lowering trials. Am J Cardiol 1998;81(4A): 70B-73B.

3. Sundquist J, Winkleby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: An analysis of NHANES 1988-1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 2001;49:109-116.

4. Gaw A. Evidence based approach for the management of mixed hyperlipidemia. Atherosclerosis 1998;137 Suppl:S97-S100.

5. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am 1998; 27:551-567.

6. Gómez-Pérez FJ, Aguilar-Salinas CA. Hiperlipoproteinemias primarias. En: Posadas C, ed. Dislipidemias y ateroesclerosis. México, D.F.: Editorial Interamericana: McGraw-Hill, 1995: 87-104.

7. Assmannn G, Schulte H. Results and conclusions of the Prospective Cardiovascular Münster (PROCAM) Study. En: Assmann G, ed. Lipid Metabolism Disorders and Coronary Heart Disease. MMV Medizin Verlag 1993: 21-67.

8. Frost P, Havel R. Rationale for use of non high density lipoprotein cholesterol rather than low density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998;81(4A): 26B-31B.

9. Sniderman AD, Vu H, Cianflone K. The effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apoB levels. Atherosclerosis 1991; 89:109-116.

10. Jiang F, Gibson AP, Dusting GJ. Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: A comparison with apolipoprotein –E deficient mice. Eur J Pharmacol 2001; 424 :141-149.

11. Jong MC, Havekes LM. Insights into apolipoprotein C metabolism from transgenic and gene targeted mice. Int J Tissue React 2000;22:59-66.

12. McGillicuddy CJ, Carrier MJ, Weinberg PD. Distribution of lipid deposits around aortic branches of mice lacking LDL receptors and apolipoprotein E. Arterios Thromb Vasc Biol 2001;21:1220-1225.

13. Chadarevian R, Brucker E, Dejager S, Presberg P, Turpin G. Relationship between triglycerides and factor VIIc and PAI-1: Lack of threshold value. Thromb Res 1999;96:175-182.

14. Li XN, Grenett HE, Benza RL, Demissie S, Brown SL, Tabengwa EM et al. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterios Thromb Vasc Biol 1997;17:3215-3223.

15. Fanghanel-Salmón G, Sánchez-Reyes L, Arellano S, Valdés S, Chavira J, Rascón A. The prevalence of risk factors for coronary disease in workers of the Hospital General de Mexico. Salud Publica Mex 1997; 39:427-432.

16. Posadas-Romero C, Tapia-Conyer R, Lerman-Garber I, Zamora- González J, Cardoso-Saldaña G, Salvatierra-Izaba B et al. Cholesterol levels and prevalence of hypercholesterolemia in a Mexican adult population. Atherosclerosis 1995;118:275-284.

17. Aguilar-Salinas CA, Olaiz G, Valles V, Ríos JM, Gómez-Pérez FJ, Rull JA et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nation wide survey. J Lipid Research 2001; 42:1298-1307.

18. Bhopal R, Unwin N, White M, Yallop J, Walker L, Alberti KGGM et al. Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: Cross sectional study. BMJ 1999; 319: 215-220.

19. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high cholesterol. JAMA 2001;285:2486-2497.

20. Ballantyne C, Grundy SM, Oberman A, Kreisberg R, Havel R, Frost P et al. Hyperlipidemia: Diagnostic and therapeutic perspectives. J Clin Endoc Metab 2000; 85:2089-2112.

21. Havel RJ, Frost P. The role of non–high-density lipoprotein cholesterol in evaluation and treatment of lipid disorders. J Clin Endocrinol Metab 2001; 85:2105-2108.

22. Matthews D, Hosler JP, Rudenski AS, Naylor BA, Treacher DF, Turner R. Homeostasis model assessment: Insulin resistance and B-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-419.

23. Taniguchi A, Fukushima M, Sakai M, Kataoka K, Nagata I, Doi K et al. The role of body mass index and triglycerides levels in identifying insulinsensitive and insulin-resistant variants in Japanese non-insulin dependent diabetic patients. Metabolism 2000; 49: 1001-1005.

24. Ballantyne C, Olsson AG, Cook TJ, Mercuri M, Pedersen T, Kjekshus J. For the Scandinavian Simvastatin Survival Study (4S) Group. Influence of low high-density lipoprotein cholesterol and elevated triglycerides in coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-3051.

25. Ezenwaka CE, Offiah NV.Cardiovascular risk in obese and nonobese patients with type 2 diabetes in the west indies. J Biomed Sci 2001;8: 314- 320.

26. Rajmohan L, Deepa R, Mohan A, Mohan V. Association between isolated hypercholesterolemia, isolated hypertriglyceridemia and coronary artery disease in south Indian type 2 diabetic patients. Indian Heart J 2000; 52:400- 406.

27. Miller M. Triglyceride as a risk factor, epidemiology. Lipids 1999;34 Suppl:S267.

28. Yarnell JWG, Patterson CC, Sweetnam PM, Thomas HF, Bainton D, Elwood PC et al. Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease? Ten-year follow- up of Caerphilly and Speedwell Cohorts. Arterios Thromb Vasc Biol 2001;21:1340-1345.

29. Grundy SM, Chait A, Brunzell J. Familial combined hyperlipidemia workshop. Arteriosclerosis 1987;7:203-207.

30. Aguilar-Salinas CA, Vázquez-Chávez C, Gamboa-Marrufo R, García-Soto N, Ríos-González JJ, Holguín R et al. Prevalence of obesity, diabetes, hypertension and tobacco consumption in an urban adult Mexican population. Arch Med Res 2001;32:446-453.

31. Eckel R. Familial combined hyperlipidemia and insulin resistance. Distant relatives linked by intra-abdominal fat? Circulation 2001;21:469-470.